The science-led skincare company will host in-booth experiences showcasing its patented AVL SOM3® technology, offering ...
Oral and poster presentations highlight first-in-human SIRT6 activator and prior Phase 2 signal in females with major depressive disorderMORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo Bio will be giving ...
ALEXANDRIA, VA / ACCESS Newswire / May 21, 2026 / The American Society of Consultant Pharmacists (ASCP) commends the House Ways & Means Committee, which oversees Medicare and Medicaid policy, for ...
A randomized, controlled study of a novel liquid embolic, NeoCast, adjunctive to surgeryWALTHAM, Mass.--(BUSINESS WIRE)--Arsenal Medical, a clinical-stage company developing innovative ...
Q1-Q2 2026 European provider-user Black Book Research survey finds data valorisation, governed secondary use, cohort discovery, trial feasibility and RWE readiness now defining the next generation of ...
New edition of the Wiley Registry of Mass Spectral Data expands compound coverage to over 915,500 reference spectra, ...
Record Q1 revenue of $17.9M, up 31% from $13.71 million in Q1 2025, reflecting strength across all core segmentsTotal liabilities decreased by $4.5M, or 9.6%, driven by a substantial reduction in ...
Zeringue brings 18 years of interventional oncology and thermal ablation leadership experience-WEST BRIDGEWATER, Mass.--(BUSINESS WIRE)--#ablation--Theromics Inc., a biotechnology company advancing ...
New survey of HIMSS26 Europe attendees finds patient-flow visibility, cyber recoverability, workflow reliability, interoperability and operational command capability are now viewed as board-level ...
The Charlotte practice welcomes Dr. Rodrigo Sarmento as it looks toward the next chapter CHARLOTTE, NC / ACCESS Newswire / May 21, 2026 / Sharma Oral Surgery, an advanced oral surgery practice founded ...
The Annual General Meeting of Cantargia AB (publ) on May 21, 2026 resolved in accordance with the following:To adopt the income statement and balance sheet as well as to allocate the company's result ...
Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant prostate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results